---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107426"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:35:22.135822+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Iovance Q3 revenue $68M (+13% QoQ), margin 43%; lifileucel NSCLC data durable

## Summary
- Q3 2025 product revenue ~$68M, up 13% sequentially; gross margin 43% on ~$39M cost of sales.
- Cash and investments ~$307M; expected to fund operations into Q2 2027.
- Full-year 2025 revenue guidance reaffirmed at $250-300M.
- Lifileucel in NSCLC: ORR 26%, median DOR not reached at >25 months; IOV-LUN-202 enrollment to complete in 2026.
- Amtagvi now at >80 U.S. authorized treatment centers; Health Canada approval in August 2025.

## SEC filing metadata
- accession: 0001104659-25-107426
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465925107426/0001104659-25-107426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465925107426/tm2530236d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107426
- JSON: https://secwatch.observer/filing/0001104659-25-107426.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107426.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.